Loading...

Daniel Johnson, PhD

Title(s)Professor, Otolaryngology
SchoolSchool of Medicine
Address1450 Third St
San Francisco CA 94158
Phone--
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Princeton UniversityPhD - Molecular Biology
    Princeton UniversityMA - Molecular Biology

    Collapse Overview 
    Collapse Overview
    Daniel Johnson, PhD, is Professor and Vice Chair of Research in the Department of Otolaryngology – Head and Neck Surgery (OHNS) at the University of California, San Francisco. He obtained a bachelor of science in chemistry and a bachelor of arts in mathematics, both from North Park University in Chicago, Illinois. Dr. Johnson earned his MA and PhD in molecular biology from Princeton University, followed by a postdoctoral fellowship at the University of California, San Francisco. Prior to joining UCSF OHNS Department in 2016, Dr. Johnson was a Professor in the Division of Hematology/Oncology, Department of Medicine, and Department of Pharmacology and Chemical Biology at the University of Pittsburgh, Pennsylvania. Dr. Johnson was also the Scientific Director of the Acute Leukemia Working group at the University of Pittsburgh Cancer Institute.

    Dr. Johnson has over 120 publications and is Editor of two books, entitled “Cell Death Signaling in Cancer Biology and Treatment” and “Targeting Cell Survival Pathways to Enhance Response to Chemotherapy”. He has maintained continuous NIH funding as a principal investigator since 1995, and has served as a standing member for both NIH and ACS study sections. Dr. Johnson continues to play an active role on multiple review panels for the NIH, VA, and other granting agencies, and serves on the Board of Scientific Counselors for NIH NIDCD. Since 2001 he has served as a Section Editor for Leukemia, the top-ranked journal for hematologic malignancies, and has also served as Editor for Cancer Research and Oncology Research. Dr. Johnson places a high priority on translating findings from his lab to the clinic, and has facilitated the development of clinical trials in both leukemia and head and neck cancer.

    Dr. Johnson greatly values teaching and serving as a mentor for individuals with a broad variety of educational backgrounds. He has served as primary mentor or co-mentor for 68 trainees. Most of his trainees have gone on to higher academic or clinical positions, including several who are now faculty members at academic institutions. He was the first lab-based faculty to be awarded the G. David Roodman Excellence in Mentorship Award by the University of Pittsburgh Hematology/Oncology Clinical Fellows. At the University of Pittsburgh he also was a leader for the Career Mentoring Program for junior faculty, and taught extensively in both the graduate and medical schools. He is a faculty member of the BMS Graduate Program at UCSF.

    Research:
    Dr. Johnson’s research is focused on understanding the molecular mechanisms that contribute to the origin and progression of head and neck squamous cell carcinoma (HNSCC), and the development of novel therapeutic agents and strategies for this disease. He is particularly interested in combating the intrinsic and acquired resistance to anti-cancer agents that characterizes the majority of HNSCC patient tumors. Work from his lab has shown that overexpression of anti-apoptotic Bcl-2 family members and/or hyperactivation of STAT3 transcription factor contribute to HNSCC drug resistance. He has employed small molecule inhibitors of Bcl-2/Bcl-XL/Mcl-1, as well as proteasome inhibitors, to develop synergistic co-targeting strategies to overcome resistance arising for overexpression of Bcl-2 family members. To combat the effects of STAT3 hyperactivation, he has co-invented an highly novel decoy oligonucleotide inhibitor for this previously undruggable oncogene. Current efforts are focused on moving the STAT3 decoy to clinical evaluation in patients with HNSCC. Additional studies in his lab have shown that mutations in caspase-8 protease, which occur frequently in HNSCC tumors, contribute to disease progression by abrogating cell death mediated by death ligands such as TRAIL and TNF. Ongoing studies are aimed at developing further in vivo and organoid models of HNSCC for investigation of drug resistance mechanisms and evaluation of novel precision medicine therapeutic strategies.

    Specialty:
    Head and Neck Oncology

    Expertise:
    Molecular biology and molecular genetics of head and neck cancer, anti-cancer drug development

    Professional Interests:
    Development of new therapeutic strategies and agents for head and neck cancer, mechanisms of chemotherapy resistance, cell death mechanisms, mentoring

    Education and Training:
    • Graduate School: Princeton University, NJ – M.A., Molecular Biology
    • Graduate School: Princeton University, NJ – Ph.D., Molecular Biology
    • Postdoctoral Fellowship: University of California, San Francisco

    Awards and Honors:
    • 2019-present - NIDCD Board of Scientific Counselors
    • 2015-present – Oncology Research Editorial Board
    • 2014 – G. David Roodman Excellence in Mentorship Award from Hematology/Oncology Fellows
    • 2010-2013 – Cancer Research Editorial Board
    • 2007 – Hillman Fellow for Innovative Cancer Research
    • 2001-present – Leukemia Section Editor
    • 1999-present – Leukemia Editorial Board
    • 1994-95 – Fellow of the Lymphoma Research Foundation of America
    • 1990 – Henry Christian Outstanding Abstract in Cardiology, AFCR
    • 1988-1992 – Fellow of the Cardiovascular Research Institute, UCSF
    • 1989 – American Heart Association Postdoctoral Fellowship
    • 1982 – Graduated summa cum laude, North Park College
    • 1981 – Walter E. Olson Memorial Scholarship Fund
    • 1981 – J. Paul Bennett Chemistry Award
    • 1980-82 – President, North Park University Mathematics Society
    • 1979 – Oscar E. Olson Memorial Scholarship Fund in Mathematics

    Collapse Research 
    Collapse Research Activities and Funding
    Targeting STAT3 to enhance anti-tumor immunity
    NIH/NIDCR R01DE028289Aug 13, 2019 - May 31, 2024
    Role: Principal Investigator
    Implications of Procaspase-8 Mutations in Oral Squamous Cell Carcinoma
    NIH/NIDCR R01DE024728Jan 1, 2016 - Dec 31, 2020
    Role: Principal Investigator
    PI3K Pathway Mutations in Head and Neck Cancer
    NIH/NIDCR R01DE023685May 1, 2014 - May 31, 2024
    Role: Co-Principal Investigator
    Molecular Targeting Strategies in HNSCC
    NIH/NCI R01CA137260Jun 15, 2010 - Apr 30, 2015
    Role: Principal Investigator
    Opposing Roles for MEK/ERK in Differentiation &Leukemia
    NIH/NCI R01CA108904Jul 1, 2005 - Apr 30, 2011
    Role: Principal Investigator
    Role of Cathepsin D in Chemotherapy Induced Cell Death
    NIH/NCI R01CA086980Jul 1, 2001 - Jun 30, 2006
    Role: Principal Investigator
    CHARACTERIZATION OF TWO NOVEL BCL-2-ASSCOCIATED PROTEINS
    NIH/NCI R29CA066044Jul 1, 1995 - Apr 30, 2001
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Student Projects

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020 Nov 26; 6(1):92. Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. PMID: 33243986.
      View in: PubMed   Mentions:    Fields:    
    2. Targeting STAT3 with proteolysis targeting chimeras (PROTACs) and next generation antisense oligonucleotides. Mol Cancer Ther. 2020 Nov 17. Shiah JV, Grandis JR, Johnson DE. PMID: 33203730.
      View in: PubMed   Mentions:    Fields:    
    3. Head and neck squamous cell carcinoma. Nature Reviews Disease Primers. In Press. 2020. Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR.
    4. CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck Cancers. Mol Cancer Res. 2020 Sep 03. Cui Z, Kang H, Grandis JR, Johnson DE. PMID: 32883697.
      View in: PubMed   Mentions:    Fields:    
    5. Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer. . 2020 07; 19(7):1562-1571. Izumi H, Wang Z, Goto Y, Ando T, Wu X, Zhang X, Li H, Johnson DE, Grandis JR, Gutkind JS. PMID: 32430488.
      View in: PubMed   Mentions:    Fields:    
    6. Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer. Biochim Biophys Acta Mol Cell Res. 2020 06; 1867(6):118679. Lee MJ, Jin N, Grandis JR, Johnson DE. PMID: 32061630.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    7. Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance. PLoS One. 2020; 15(1):e0227261. O'Keefe RA, Bhola NE, Lee DS, Johnson DE, Grandis JR. PMID: 31914141.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    8. Targeting STAT3 in Cancer with Nucleotide Therapeutics. Cancers (Basel). 2019 10 29; 11(11). Lau YK, Ramaiyer M, Johnson DE, Grandis JR. PMID: 31671769.
      View in: PubMed   Mentions:
    9. Gene targets of sulforaphane in head and neck squamous cell carcinoma. Mol Med Rep. 2019 Dec; 20(6):5335-5344. Hu L, Li H, Lee ED, Grandis JR, Bauman JE, Johnson DE. PMID: 31661135.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    10. NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer. Adv Biol Regul. 2020 01; 75:100653. Cai Y, Yousef A, Grandis JR, Johnson DE. PMID: 31594701.
      View in: PubMed   Mentions: 2     Fields:    
    11. ATR inhibition sensitizes HPV- and HPV+ head and neck squamous cell carcinoma to cisplatin. Oral Oncol. 2019 08; 95:35-42. Leonard BC, Lee ED, Bhola NE, Li H, Sogaard KK, Bakkenist CJ, Grandis JR, Johnson DE. PMID: 31345392.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    12. Investigational multitargeted kinase inhibitors in development for head and neck neoplasms. Expert Opin Investig Drugs. 2019 04; 28(4):351-363. Sola AM, Johnson DE, Grandis JR. PMID: 30753792.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    13. Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer. J Exp Med. 2019 02 04; 216(2):419-427. Hedberg ML, Peyser ND, Bauman JE, Gooding WE, Li H, Bhola NE, Zhu TR, Zeng Y, Brand TM, Kim MO, Jordan RCK, VandenBerg S, Olivas V, Bivona TG, Chiosea SI, Wang L, Mills GB, Johnson JT, Duvvuri U, Ferris RL, Ha P, Johnson DE, Grandis JR. PMID: 30683736.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCTClinical Trials
    14. Modulation of the PI3K/mTOR pathways. In: Improving the therapeutic ratio in head and neck cancer. Editor: Randy Kimple. Elsevier. Pgs. 89-105. ISBN: 978-0-12-817868-3. 2019. Galstyan A, Cho J, Johnson DE, Grandis JR.
    15. An update: emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs. 2018 12; 23(4):283-299. Lee YS, Johnson DE, Grandis JR. PMID: 30376740.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    16. STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer. . 2018 09; 17(9):1917-1926. Njatcha C, Farooqui M, Kornberg A, Johnson DE, Grandis JR, Siegfried JM. PMID: 29891486.
      View in: PubMed   Mentions:
    17. Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor. Int J Mol Sci. 2018 May 30; 19(6). Lee DS, O'Keefe RA, Ha PK, Grandis JR, Johnson DE. PMID: 29848966.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    18. New Therapies in Head and Neck Cancer. Trends Cancer. 2018 05; 4(5):385-396. Santuray RT, Johnson DE, Grandis JR. PMID: 29709262.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    19. A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Leuk Lymphoma. 2018 11; 59(11):2595-2601. Redner RL, Beumer JH, Kropf P, Agha M, Boyiadzis M, Dorritie K, Farah R, Hou JZ, Im A, Lim SH, Raptis A, Sehgal A, Christner SM, Normolle D, Johnson DE. PMID: 29616864.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    20. Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer Res. 2018 05 01; 78(9):2383-2395. Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR. PMID: 29440171.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    21. Leveraging Genomics for Head and Neck Cancer Treatment. J Dent Res. 2018 06; 97(6):603-613. Kemmer JD, Johnson DE, Grandis JR. PMID: 29420101.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    22. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018 04; 15(4):234-248. Johnson DE, O'Keefe RA, Grandis JR. PMID: 29405201.
      View in: PubMed   Mentions: 231     Fields:    Translation:HumansCells
    23. Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer. Semin Radiat Oncol. 2018 01; 28(1):2-11. Cho J, Johnson DE, Grandis JR. PMID: 29173752.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    24. Targeting members of the epidermal growth factor receptor family to improve response to chemotherapy. In: Targeting Cell Survival Pathways to Enhance Response to Chemotherapy. Chapter 1, pgs. 1-23. Editor: DE Johnson. Elsevier. ISBN: 978-0-12-816432-7,. 2018. O’Keefe RA, Grandis JR, Johnson DE. .
    25. The JNK pathway in drug resistance. In: Targeting Cell Survival Pathways to Enhance Response to Chemotherapy. Chapter 4, pgs. 87-100. Editor: DE Johnson. Elsevier. ISBN: 978-0-12-816432-7,. 2018. Hu L, Zou F, Grandis JR, Johnson DE. .
    26. PIK3CA mutations in colorectal and breast cancer: impact on oncogenesis and response to nonsteroidal anti-inflammatory drugs. In: Targeting Cell Survival Pathways to Enhance Response to Chemotherapy. Chapter 6, pgs. 123-144. Editor: DE Johnson. Elsevier. ISBN: 978-0-12-816432-7,. 2018. Zhu RT, Gutkind JS, Johnson DE, Grandis JR.
    27. STAT3 as a major contributor to chemoresistance. In: Targeting Cell Survival Pathways to Enhance Response to Chemotherapy. Chapter 7, pgs. 145-167. Editor: DE Johnson. Elsevier. ISBN: 978-0-12-816432-7,. 2018. Lee DS, Grandis JR, Johnson DE. .
    28. Jak/STAT signaling in head and neck cancer. In: Molecular Determinants of Head and Neck Cancer. Editors: Burtness B and Golemis E. Springer. Pgs. 155-184. ISBN: 978-3-319-78762-6. 2018. Cedars E, Johnson DE, Grandis JR.
    29. Signaling by cell surface death receptors: Alterations in head and neck cancer. Adv Biol Regul. 2018 01; 67:170-178. Leonard BC, Johnson DE. PMID: 29066276.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    30. EGFR-targeted therapies in the post-genomic era. Cancer Metastasis Rev. 2017 09; 36(3):463-473. Xu MJ, Johnson DE, Grandis JR. PMID: 28866730.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimals
    31. When the Damage Is Done: Selecting Patients for Head and Neck Cancer Chemoprevention Trials. Cancer Prev Res (Phila). 2017 09; 10(9):489-490. Johnson DE, Bauman JE. PMID: 28821544.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    32. Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients. Clin Cancer Res. 2017 Jun 15; 23(12):3072-3083. Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR. PMID: 27986750.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    33. Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer. PLoS One. 2016; 11(11):e0166185. Peyser ND, Pendleton K, Gooding WE, Lui VW, Johnson DE, Grandis JR. PMID: 27855189.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    34. A sensible approach to targeting STAT3-mediated transcription. Ann Transl Med. 2016 Oct; 4(Suppl 1):S57. Bhola NE, Johnson DE, Grandis JR. PMID: 27868025.
      View in: PubMed   Mentions:
    35. Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane. Cancer Prev Res (Phila). 2016 Jul; 9(7):547-57. Bauman JE, Zang Y, Sen M, Li C, Wang L, Egner PA, Fahey JW, Normolle DP, Grandis JR, Kensler TW, Johnson DE. PMID: 27339168.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    36. STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma. Cancer Prev Res (Phila). 2016 Aug; 9(8):657-63. Peyser ND, Wang L, Zeng Y, Acquafondata M, Freilino M, Li H, Sen M, Gooding WE, Satake M, Wang Z, Johnson DE, Grandis JR. PMID: 27267892.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    37. Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer. Oncogene. 2016 Mar 03; 35(9):1163-9. Peyser ND, Freilino M, Wang L, Zeng Y, Li H, Johnson DE, Grandis JR. PMID: 25982282.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    38. Chemoprevention targets for tobacco-related head and neck cancer: past lessons and future directions. Oral Oncol. 2015 Jun; 51(6):557-64. Sheth SH, Johnson DE, Kensler TW, Bauman JE. PMID: 25868717.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    39. An ATRActive future for differentiation therapy in AML. Blood Rev. 2015 Jul; 29(4):263-8. Johnson DE, Redner RL. PMID: 25631637.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    40. Overcoming inherent resistance to proteasome inhibitors in head and neck cancer: challenges and new Approaches. In: Resistance to Proteasome Inhibitors in Cancer. Editor: Q. Ping Dou. Springer. ISBN: 978-3-319-06752-0. 2015. Kass JI, Grandis JR, and Johnson DE. .
    41. You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia. Leukemia. 2015 Mar; 29(3):517-25. Sehgal AR, Konig H, Johnson DE, Tang D, Amaravadi RK, Boyiadzis M, Lotze MT. PMID: 25541151.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    42. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors. . 2014 Sep; 15(9):1142-52. Zang Y, Kirk CJ, Johnson DE. PMID: 24915039.
      View in: PubMed   Mentions:
    43. STAT transcription factors in normal and cancer stem cells. Adv Biol Regul. 2014 Sep; 56:30-44. Dorritie KA, Redner RL, Johnson DE. PMID: 24931719.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    44. Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth. Mol Oncol. 2014 Oct; 8(7):1220-30. Li C, Egloff AM, Sen M, Grandis JR, Johnson DE. PMID: 24816188.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    45. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia. 2014 Sep; 28(9):1774-83. Im AP, Sehgal AR, Carroll MP, Smith BD, Tefferi A, Johnson DE, Boyiadzis M. PMID: 24699305.
      View in: PubMed   Mentions: 75     Fields:    Translation:Humans
    46. The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors. Endocr Relat Cancer. 2015 Feb; 22(1):T1-17. Johnson DE. PMID: 24659480.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimals
    47. Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects. Mol Med. 2014 Mar 18; 20:46-56. Sen M, Paul K, Freilino ML, Li H, Li C, Johnson DE, Wang L, Eiseman J, Grandis JR. PMID: 24395569.
      View in: PubMed   Mentions: 16     Fields:    Translation:Animals
    48. Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):1114-9. Lui VW, Peyser ND, Ng PK, Hritz J, Zeng Y, Lu Y, Li H, Wang L, Gilbert BR, General IJ, Bahar I, Ju Z, Wang Z, Pendleton KP, Xiao X, Du Y, Vries JK, Hammerman PS, Garraway LA, Mills GB, Johnson DE, Grandis JR. PMID: 24395800.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    49. Single-agent obatoclax (GX15-070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells. Oral Oncol. 2014 Feb; 50(2):120-7. Yazbeck VY, Li C, Grandis JR, Zang Y, Johnson DE. PMID: 24216166.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    50. STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia. 2014 Feb; 28(2):248-57. Dorritie KA, McCubrey JA, Johnson DE. PMID: 23797472.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    51. Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest. . 2013 Mar 15; 12(6):923-34. Li C, Johnson DE. PMID: 23421999.
      View in: PubMed   Mentions:
    52. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4. Autophagy. 2012 Dec; 8(12):1873-4. Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE. PMID: 22995770.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    53. Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clin Cancer Res. 2012 Oct 15; 18(20):5639-49. Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE. PMID: 22929803.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    54. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res. 2012 Sep 15; 18(18):4986-96. Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, Wang L, Gooding WE, Johnson DE, Grandis JR. PMID: 22825581.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimalsCells
    55. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov. 2012 Aug; 2(8):694-705. Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee J, Sahu N, Joyce S, Freilino ML, Shi H, Li C, Ly D, Rapireddy S, Etter JP, Li PK, Wang L, Chiosea S, Seethala RR, Gooding WE, Chen X, Kaminski N, Pandit K, Johnson DE, Grandis JR. PMID: 22719020.
      View in: PubMed   Mentions: 118     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    56. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr; 8(4):445-544. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Bánhegyi G, Bartholomew CR, Bassham DC, Bast RC, Batoko H, Bay BH, Beau I, Béchet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahová M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Choi KS, Choi ME, Chouaib S, Choubey D, Choubey V, Chu CT, Chuang TH, Chueh SH, Chun T, Chwae YJ, Chye ML, Ciarcia R, Ciriolo MR, Clague MJ, Clark RS, Clarke PG, Clarke R, Codogno P, Coller HA, Colombo MI, Comincini S, Condello M, Condorelli F, Cookson MR, Coombs GH, Coppens I, Corbalan R, Cossart P, Costelli P, Costes S, Coto-Montes A, Couve E, Coxon FP, Cregg JM, Crespo JL, Cronjé MJ, Cuervo AM, Cullen JJ, Czaja MJ, D'Amelio M, Darfeuille-Michaud A, Davids LM, Davies FE, De Felici M, de Groot JF, de Haan CA, De Martino L, De Milito A, De Tata V, Debnath J, Degterev A, Dehay B, Delbridge LM, Demarchi F, Deng YZ, Dengjel J, Dent P, Denton D, Deretic V, Desai SD, Devenish RJ, Di Gioacchino M, Di Paolo G, Di Pietro C, Díaz-Araya G, Díaz-Laviada I, Diaz-Meco MT, Diaz-Nido J, Dikic I, Dinesh-Kumar SP, Ding WX, Distelhorst CW, Diwan A, Djavaheri-Mergny M, Dokudovskaya S, Dong Z, Dorsey FC, Dosenko V, Dowling JJ, Doxsey S, Dreux M, Drew ME, Duan Q, Duchosal MA, Duff K, Dugail I, Durbeej M, Duszenko M, Edelstein CL, Edinger AL, Egea G, Eichinger L, Eissa NT, Ekmekcioglu S, El-Deiry WS, Elazar Z, Elgendy M, Ellerby LM, Eng KE, Engelbrecht AM, Engelender S, Erenpreisa J, Escalante R, Esclatine A, Eskelinen EL, Espert L, Espina V, Fan H, Fan J, Fan QW, Fan Z, Fang S, Fang Y, Fanto M, Fanzani A, Farkas T, Farré JC, Faure M, Fechheimer M, Feng CG, Feng J, Feng Q, Feng Y, Fésüs L, Feuer R, Figueiredo-Pereira ME, Fimia GM, Fingar DC, Finkbeiner S, Finkel T, Finley KD, Fiorito F, Fisher EA, Fisher PB, Flajolet M, Florez-McClure ML, Florio S, Fon EA, Fornai F, Fortunato F, Fotedar R, Fowler DH, Fox HS, Franco R, Frankel LB, Fransen M, Fuentes JM, Fueyo J, Fujii J, Fujisaki K, Fujita E, Fukuda M, Furukawa RH, Gaestel M, Gailly P, Gajewska M, Galliot B, Galy V, Ganesh S, Ganetzky B, Ganley IG, Gao FB, Gao GF, Gao J, Garcia L, Garcia-Manero G, Garcia-Marcos M, Garmyn M, Gartel AL, Gatti E, Gautel M, Gawriluk TR, Gegg ME, Geng J, Germain M, Gestwicki JE, Gewirtz DA, Ghavami S, et al. PMID: 22966490.
      View in: PubMed   Mentions: 1521     Fields:    Translation:HumansAnimals
    57. Targeting proliferation and survival pathways in head and neck cancer for therapeutic benefit. Chin J Cancer. 2012 Jul; 31(7):319-26. Johnson DE. PMID: 22257382.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    58. Defective apoptosis signaling in cancer. In: Cell Death Signaling in Cancer Biology and Treatment. Chapter 1, pgs. 1-34. Editor: DE Johnson. Springer. ISBN: 978-1-4614-5846-3,. 2012. Johnson DE. .
    59. Leading small molecule inhibitors of anti-apoptotic Bcl-2 family members. In: Cell Death Signaling in Cancer Biology and Treatment. Chapter 9, pgs. 231-253. Editor: DE Johnson. Springer. ISBN: 978-1-4614-5846-3,. 2012. Yazbeck VY and Johnson DE. .
    60. Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation. Cancer Lett. 2012 Jan 01; 314(1):102-7. Li C, Johnson DE. PMID: 21993018.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    61. Dasatinib promotes ATRA-induced differentiation of AML cells. Leukemia. 2010 Mar; 24(3):663-5. Kropf PL, Wang L, Zang Y, Redner RL, Johnson DE. PMID: 20033056.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    62. Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis. 2009 Nov; 30(11):1848-56. Leeman-Neill RJ, Wheeler SE, Singh SV, Thomas SM, Seethala RR, Neill DB, Panahandeh MC, Hahm ER, Joyce SC, Sen M, Cai Q, Freilino ML, Li C, Johnson DE, Grandis JR. PMID: 19762335.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    63. CD13+CD4+CD25hi regulatory T cells exhibit higher suppressive function and increase with tumor stage in non-small cell lung cancer patients. . 2009 Aug 15; 8(16):2578-85. Ju S, Qiu H, Zhou X, Zhu B, Lv X, Huang X, Li J, Zhang Y, Liu L, Ge Y, Johnson DE, Ju S, Shu Y. PMID: 19597336.
      View in: PubMed   Mentions:
    64. Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. . 2009 Aug; 8(8):2211-20. Li C, Zang Y, Sen M, Leeman-Neill RJ, Man DS, Grandis JR, Johnson DE. PMID: 19638453.
      View in: PubMed   Mentions:
    65. Src family kinase gene targets during myeloid differentiation: identification of the EGR-1 gene as a direct target. Leukemia. 2009 Oct; 23(10):1933-5. Jones JE, Wang L, Kropf PL, Duan R, Johnson DE. PMID: 19494839.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    66. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Mol Pharmacol. 2009 May; 75(5):1231-9. Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE. PMID: 19246337.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    67. Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol. 2009 May; 63(6):983-95. Sen M, Tosca PJ, Zwayer C, Ryan MJ, Johnson JD, Knostman KA, Giclas PC, Peggins JO, Tomaszewski JE, McMurray TP, Li C, Leibowitz MS, Ferris RL, Gooding WE, Thomas SM, Johnson DE, Grandis JR. PMID: 18766340.
      View in: PubMed   Mentions: 24     Fields:    Translation:Animals
    68. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. . 2008 Jun; 7(6):1647-55. Li C, Li R, Grandis JR, Johnson DE. PMID: 18566236.
      View in: PubMed   Mentions:
    69. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol Pharmacol. 2008 Jun; 73(6):1632-42. Boehm AL, Sen M, Seethala R, Gooding WE, Freilino M, Wong SM, Wang S, Johnson DE, Grandis JR. PMID: 18326051.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    70. Gefitinib potentiates myeloid cell differentiation by ATRA. Leukemia. 2008 Aug; 22(8):1624-7. Miranda MB, Duan R, Thomas SM, Grandis JR, Redner RL, Jones JE, Johnson DE. PMID: 18305561.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    71. Inhibitors of the Bcl-2 protein family as sensitizers to anticancer agents. In: Sensitization of Cancer Cells to Chemo/Immuno/Radio Therapy. Editors: B Bonavida and B Teicher. Humana Press, Inc., pgs. 243-261. ISBN: 978-1-59745-474-2. 2008. Johnson DE. .
    72. Inhibition of Src family kinases enhances retinoic acid induced gene expression and myeloid differentiation. . 2007 Dec; 6(12 Pt 1):3081-90. Miranda MB, Redner RL, Johnson DE. PMID: 18065491.
      View in: PubMed   Mentions:
    73. Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis. Adv Enzyme Regul. 2008; 48:98-112. Johnson DE. PMID: 18155170.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    74. Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells. Neoplasia. 2007 Oct; 9(10):801-11. Li R, Boehm AL, Miranda MB, Shangary S, Grandis JR, Johnson DE. PMID: 17971900.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    75. Signal transduction pathways that contribute to myeloid differentiation. Leukemia. 2007 Jul; 21(7):1363-77. Miranda MB, Johnson DE. PMID: 17443228.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    76. Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1. Mol Pharmacol. 2007 May; 71(5):1435-43. Lui VW, Boehm AL, Koppikar P, Leeman RJ, Johnson D, Ogagan M, Childs E, Freilino M, Grandis JR. PMID: 17325127.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    77. Sulforaphane causes autophagy to inhibit release of cytochrome C and apoptosis in human prostate cancer cells. Cancer Res. 2006 Jun 01; 66(11):5828-35. Herman-Antosiewicz A, Johnson DE, Singh SV. PMID: 16740722.
      View in: PubMed   Mentions: 109     Fields:    Translation:HumansCells
    78. Cytokine-induced myeloid differentiation is dependent on activation of the MEK/ERK pathway. Leuk Res. 2005 Nov; 29(11):1293-306. Miranda MB, Xu H, Torchia JA, Johnson DE. PMID: 16164983.
      View in: PubMed   Mentions: 18     Fields:    Translation:AnimalsCells
    79. Involvement of cathepsin D in chemotherapy-induced cytochrome c release, caspase activation, and cell death. . 2005 May; 4(5):733-42. Emert-Sedlak L, Shangary S, Rabinovitz A, Miranda MB, Delach SM, Johnson DE. PMID: 15897237.
      View in: PubMed   Mentions:
    80. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. . 2005 Jan; 4(1):23-31. Oliver CL, Miranda MB, Shangary S, Land S, Wang S, Johnson DE. PMID: 15657350.
      View in: PubMed   Mentions:
    81. Sequence and helicity requirements for the proapoptotic activity of Bax BH3 peptides. . 2004 Nov; 3(11):1343-54. Shangary S, Oliver CL, Tillman TS, Cascio M, Johnson DE. PMID: 15542773.
      View in: PubMed   Mentions:
    82. Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2. Oncogene. 2004 Jul 22; 23(33):5594-606. Xiao D, Choi S, Johnson DE, Vogel VG, Johnson CS, Trump DL, Lee YJ, Singh SV. PMID: 15184882.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansCells
    83. The intrinsic (mitochondrial) death pathway and new cancer therapeutics: Bcl-2 family in focus. In: Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases. Editors: M Los and SB Gibson. Kluwer Academic Press. ISBN: 0-387-23384-9,. 2004. Shangary S, Oliver CL, Johnson DE. .
    84. Responsiveness to the retinoic acid receptor-selective retinoid LGD1550 correlates with abrogation of transforming growth factor alpha/epidermal growth factor receptor autocrine signaling in head and neck squamous carcinoma cells. Clin Cancer Res. 2003 Sep 15; 9(11):4205-13. Lango M, Wentzel AL, Song JI, Xi S, Johnson DE, Lamph WW, Miller L, Grandis JR. PMID: 14519647.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    85. Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family. Leukemia. 2003 Aug; 17(8):1470-81. Shangary S, Johnson DE. PMID: 12886234.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    86. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A. 2003 Apr 01; 100(7):4138-43. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF, Grandis JR. PMID: 12640143.
      View in: PubMed   Mentions: 113     Fields:    Translation:HumansCells
    87. Differential activation of apoptosis regulatory pathways during monocytic vs granulocytic differentiation: a requirement for Bcl-X(L)and XIAP in the prolonged survival of monocytic cells. Leukemia. 2003 Feb; 17(2):390-400. Miranda MB, Dyer KF, Grandis JR, Johnson DE. PMID: 12592339.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    88. Potentiation of tumor necrosis factor-alpha-induced cell death by rottlerin through a cytochrome-C-independent pathway. Exp Cell Res. 2002 Aug 15; 278(2):209-14. Basu A, Johnson DE, Woolard MD. PMID: 12169276.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    89. Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax oligomerization, induction of cytochrome c release, and activation of cell death. Biochemistry. 2002 Jul 30; 41(30):9485-95. Shangary S, Johnson DE. PMID: 12135371.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    90. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines. Leukemia. 2002 Apr; 16(4):683-92. Miranda MB, McGuire TF, Johnson DE. PMID: 11960350.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    91. Isolation of Bcl-2 binding proteins that exhibit homology with BAG-1 and suppressor of death domains protein. Biochem Biophys Res Commun. 2001 Sep 07; 286(5):1003-10. Antoku K, Maser RS, Scully WJ, Delach SM, Johnson DE. PMID: 11527400.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    92. A distinct pathway of cell-mediated apoptosis initiated by granulysin. J Immunol. 2001 Jul 01; 167(1):350-6. Kaspar AA, Okada S, Kumar J, Poulain FR, Drouvalakis KA, Kelekar A, Hanson DA, Kluck RM, Hitoshi Y, Johnson DE, Froelich CJ, Thompson CB, Newmeyer DD, Anel A, Clayberger C, Krensky AM. PMID: 11418670.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    93. Sequential two-step cleavage of the retinoblastoma protein by caspase-3/-7 during etoposide-induced apoptosis. Oncogene. 2001 May 24; 20(23):2918-26. Fattman CL, Delach SM, Dou QP, Johnson DE. PMID: 11420704.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    94. Tumor-induced apoptosis of T cells: amplification by a mitochondrial cascade. Cancer Res. 2000 Dec 15; 60(24):6811-7. Gastman BR, Yin XM, Johnson DE, Wieckowski E, Wang GQ, Watkins SC, Rabinowich H. PMID: 11156370.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    95. Analysis of the role of conserved cysteine residues in the bcl-2 oncoprotein. Biochem Biophys Res Commun. 2000 Oct 14; 277(1):171-8. Maser RS, Antoku K, Scully WJ, Cho RL, Johnson DE. PMID: 11027659.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    96. p21WAF1 prevents down-modulation of the apoptotic inhibitor protein c-IAP1 and inhibits leukemic apoptosis. Mol Med. 2000 Sep; 6(9):736-49. Steinman RA, Johnson DE. PMID: 11071269.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    97. Noncaspase proteases in apoptosis. Leukemia. 2000 Sep; 14(9):1695-703. Johnson DE. PMID: 10995018.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    98. Programmed cell death regulation: basic mechanisms and therapeutic opportunities. Leukemia. 2000 Aug; 14(8):1340-4. Johnson DE. PMID: 10942226.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    99. Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes deltapsim loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp Cell Res. 2000 Jul 10; 258(1):223-35. Gamen S, Anel A, Pérez-Galán P, Lasierra P, Johnson D, Piñeiro A, Naval J. PMID: 10912804.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    100. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A. 2000 Apr 11; 97(8):4227-32. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y, Kim JD. PMID: 10760290.
      View in: PubMed   Mentions: 180     Fields:    Translation:HumansAnimalsCells
    101. Inhibitor of apoptosis protein hILP undergoes caspase-mediated cleavage during T lymphocyte apoptosis. Cancer Res. 2000 Apr 01; 60(7):1818-23. Johnson DE, Gastman BR, Wieckowski E, Wang GQ, Amoscato A, Delach SM, Rabinowich H. PMID: 10766165.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    102. Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. Blood. 2000 Mar 15; 95(6):2015-23. Gastman BR, Johnson DE, Whiteside TL, Rabinowich H. PMID: 10706869.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    103. Characterization of caspase proteases in cytokine-dependent myeloid progenitor cells using enzyme affinity labeling. J Cell Biochem. 1999 Apr 01; 73(1):79-89. Cho RL, Johnson DE. PMID: 10088726.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    104. Caspase-mediated degradation of T-cell receptor zeta-chain. Cancer Res. 1999 Apr 01; 59(7):1422-7. Gastman BR, Johnson DE, Whiteside TL, Rabinowich H. PMID: 10197606.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    105. Bcl-2 but not Bax expression is associated with apoptosis in normal and transformed squamous epithelium. Clin Cancer Res. 1998 Nov; 4(11):2913-21. Drenning SD, Marcovitch AJ, Johnson DE, Melhem MF, Tweardy DJ, Grandis JR. PMID: 9829760.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    106. IL-3 withdrawal activates a CrmA-insensitive poly(ADP-ribose) polymerase cleavage enzyme in factor-dependent myeloid progenitor cells. Leukemia. 1998 May; 12(5):682-9. Antoku K, Liu Z, Johnson DE. PMID: 9593265.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    107. Regulation of survival pathways by IL-3 and induction of apoptosis following IL-3 withdrawal. Front Biosci. 1998 Mar 15; 3:d313-24. Johnson DE. PMID: 9488657.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    108. Bcl-2- and CrmA-inhibitable dephosphorylation and cleavage of retinoblastoma protein during etoposide-induced apoptosis. Int J Mol Med. 1998 Jan; 1(1):131-6. An B, Johnson DE, Jin JR, Antoku K, Dou QP. PMID: 9852210.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    109. Inhibition of caspase proteases by CrmA enhances the resistance of human leukemic cells to multiple chemotherapeutic agents. Leukemia. 1997 Oct; 11(10):1665-72. Antoku K, Liu Z, Johnson DE. PMID: 9324287.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    110. Fas stimulation induces RB dephosphorylation and proteolysis that is blocked by inhibitors of the ICE protease family. J Cell Biochem. 1997 Mar 15; 64(4):586-94. Dou QP, An B, Antoku K, Johnson DE. PMID: 9093908.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    111. Bcl-2 inhibits selective oxidation and externalization of phosphatidylserine during paraquat-induced apoptosis. Am J Physiol. 1997 Feb; 272(2 Pt 1):C675-84. Fabisiak JP, Kagan VE, Ritov VB, Johnson DE, Lazo JS. PMID: 9124312.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    112. A novel promoter for vascular endothelial growth factor receptor (flt-1) that confers endothelial-specific gene expression. J Biol Chem. 1995 Nov 17; 270(46):27948-53. Morishita K, Johnson DE, Williams LT. PMID: 7499271.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    113. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res. 1993; 60:1-41. Johnson DE, Williams LT. PMID: 8417497.
      View in: PubMed   Mentions: 230     Fields:    Translation:HumansAnimalsCells
    114. Signalling by receptor tyrosine kinases. Annu Rev Biochem. 1993; 62:453-81. Fantl WJ, Johnson DE, Williams LT. PMID: 7688944.
      View in: PubMed   Mentions: 200     Fields:    Translation:AnimalsCells
    115. Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities. Mol Cell Biol. 1992 Jan; 12(1):82-8. Werner S, Duan DS, de Vries C, Peters KG, Johnson DE, Williams LT. PMID: 1309595.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimalsCells
    116. The human fibroblast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain. Mol Cell Biol. 1991 Sep; 11(9):4627-34. Johnson DE, Lu J, Chen H, Werner S, Williams LT. PMID: 1652059.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansCells
    117. Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. Proc Natl Acad Sci U S A. 1991 Feb 15; 88(4):1095-9. Keegan K, Johnson DE, Williams LT, Hayman MJ. PMID: 1847508.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansAnimalsCells
    118. Characterization of the FGFR-3 gene and its gene product. Ann N Y Acad Sci. 1991; 638:400-2. Keegan K, Johnson DE, Williams LT, Hayman MJ. PMID: 1723860.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    119. Diverse forms of a receptor for acidic and basic fibroblast growth factors. Mol Cell Biol. 1990 Sep; 10(9):4728-36. Johnson DE, Lee PL, Lu J, Williams LT. PMID: 2167437.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansAnimalsCells
    120. Purification and complementary DNA cloning of a receptor for basic fibroblast growth factor. Science. 1989 Jul 07; 245(4913):57-60. Lee PL, Johnson DE, Cousens LS, Fried VA, Williams LT. PMID: 2544996.
      View in: PubMed   Mentions: 126     Fields:    Translation:AnimalsCells
    121. DNA polymorphisms for the nerve growth factor receptor gene exclude its role in familial dysautonomia. Mol Biol Med. 1986 Dec; 3(6):483-94. Breakefield XO, Ozelius L, Bothwell MA, Chao MV, Axelrod F, Kramer PL, Kidd KK, Lanahan AA, Johnson DE, Ross AH. PMID: 2886891.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    122. Expression and structure of the human NGF receptor. Cell. 1986 Nov 21; 47(4):545-54. Johnson D, Lanahan A, Buck CR, Sehgal A, Morgan C, Mercer E, Bothwell M, Chao M. PMID: 3022937.
      View in: PubMed   Mentions: 161     Fields:    Translation:HumansAnimalsCells
    123. The epidermal growth factor (EGF) receptor gene studied using gene transfer. Int J Neurosci. 1985 Apr; 26(1-2):129-40. Strazdis J, Lanahan A, Johnson DE, Bothwell M, Kucherlapati R. PMID: 2987144.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    Daniel's Networks
    Concepts (482)
    Derived automatically from this person's publications.
    _
    Co-Authors (31)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _